|Bid||16.28 x 800|
|Ask||19.00 x 1100|
|Day's Range||16.35 - 17.34|
|52 Week Range||16.35 - 52.43|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||42.48|
|Earnings Date||Mar 22, 2022 - Mar 28, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||49.80|
iTeos Therapeutics, Inc. ( NASDAQ:ITOS ) shareholders will have a reason to smile today, with the analysts making...
iTeos Therapeutics, Inc. (ITOS) delivered earnings and revenue surprises of 127.50% and 140.95%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Enrolling patients with multiple myeloma in clinical trial of anti-TIGIT monoclonal antibody, EOS-448/GSK4428859A in monotherapy and in combination with BMS’s novel CELMoD agent, iberdomide.Enrolling patients in the biomarker cohort in an ongoing clinical trial of inupadenant, an A2A receptor antagonist, as a monotherapy in patients with solid tumors expressing high levels of A2A to explore observed relationship between A2A levels and clinical benefitPresented updated preclinical and clinical an